Table 2 Detailed on subgroups analysis based on drug types, target, and PD-L1 cutoff
From: Immune checkpoint inhibitors in gastrointestinal malignancies: an Umbrella review
| Â | OS | PFS | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
HR | 95% CI | No. of trails | I2(P-value) | P interaction | HR | 95% CI | No. of trails | I2(P-value) | P interaction | |
A) Drug | 0.002 | Â | 0.000 | |||||||
 Pembrolizumab | 0.83 | (0.78, 0.89) | 11 | 0.0%, (0.560) |  | 0.92 | (0.74, 1.14) | 11 | 91.5%, (0.000) |  |
 Nivolumab | 0.79 | (0.73, 0.84) | 6 | 33.3%, (0.186) |  | 0.92 | (0.74, 1.14) | 6 | 91.3%, (0.000) |  |
 Atezolizumab | 0.83 | (0.73, 0.94) | 6 | 60.8%, (0.026) |  | 0.93 | (0.72, 1.19) | 6 | 79.9%, (0.000) |  |
 Sintilimab | 0.70 | (0.63, 0.77) | 5 | 12.5%, (0.334) |  | 0.64 | (0.55, 0.75) | 5 | 60.7%, (0.038) |  |
 Durvalumab | 0.84 | (0.75, 0.95) | 3 | 0.0%, (0.737) |  | 0.88 | (0.79, 0.98) | 3 | 73.3%, (0.024) |  |
 Camrelizumab | 0.68 | (0.60, 0.77) | 3 | 0.0%, (0.681) |  | 0.59 | (0.50, 0.69) | 3 | 42.3%, (0.177) |  |
 Durvalumab + Tremelimumab | 0.79 | (0.69, 0.91) | 3 | 0.0%, (0.495) |  | 0.93 | (0.82, 1.06) | 3 | 0.0%, (0.743) |  |
 Tislelizumab | 0.78 | (0.68, 0.89) | 2 | 50.2%, (0.156) |  | 1.10 | (0.91, 1.32) | 1 | NA |  |
 Avelumab | 0.99 | (0.85, 1.15) | 2 | 34.9%, (0.215) |  | 1.34 | (0.81, 2.20) | 2 | 90.7%, (0.001) |  |
 Nivolumab + Ipilimumab | 0.85 | (0.75, 0.96) | 2 | 33.1%, (0.222) |  | 1.47 | (1.30, 1.67) | 2 | 78.3%, (0.032) |  |
 Ipilimumab | 0.95 | (0.59, 1.51) | 1 | NA |  | - | - | - | - |  |
 Toripalimab | 0.58 | (0.43, 0.78) | 1 | NA |  | 0.58 | (0.46, 0.74) | 1 | NA |  |
B) Target | 0.058 | Â | 0.000 | |||||||
 PD-1 | 0.78 | (0.75, 0.81) | 28 | 33.3%, (0.046) |  | 0.82 | (0.72, 0.93) | 28 | 89.1%, (0.000) |  |
 PD-L1 | 0.87 | (0.81, 0.93) | 11 | 46.5%, (0.044) |  | 0.97 | (0.83, 1.14) | 11 | 84.1%, (0.000) |  |
 PD-L1 + CTLA-4 | 0.79 | (0.69, 0.91) | 3 | 0.0%, (0.495) |  | 0.93 | (0.82, 1.06) | 3 | 0.0%, (0.743) |  |
 PD-1 + CTLA-4 | 0.85 | (0.75, 0.96) | 2 | 33.1%, (0.222) |  | 1.47 | (1.30, 1.67) | 2 | 78.3%, (0.032) |  |
 CTLA-4 | 0.95 | (0.59, 1.51) | 1 | NA |  | - | - | - | - |  |
C) PD-L1 cutoff | ||||||||||
CPS = 1 |  |  |  |  | 0.000 |  |  |  |  | 0.475 |
 CPS ≥ 1 | 0.76 | (0.72, 0.81) | 13 | 40.4%, (0.065) |  | 0.91 | (0.71, 1.16) | 10 | 91.1%, (0.000) |  |
 CPS < 1 | 1.03 | (0.88, 1.19) | 9 | 0.0%, (0.819) |  | 1.08 | (0.72, 1.61) | 6 | 75.5%, (0.001) |  |
CPS = 5 |  |  |  |  | 0.002 |  |  |  |  | 0.758 |
 CPS ≥ 5 | 0.70 | (0.65, 0.76) | 9 | 0.0%, (0.488) |  | 0.76 | (0.59, 0.97) | 7 | 87.2%, (0.000) |  |
 CPS < 5 | 0.87 | (0.78, 0.97) | 6 | 29.9%, (0.211) |  | 0.82 | (0.55, 1.21) | 3 | 79.1%, (0.008) |  |
CPS = 10 |  |  |  |  | 0.014 |  |  |  |  | 0.701 |
 CPS ≥ 10 | 0.69 | (0.63, 0.76) | 12 | 0.0%, (0.512) |  | 0.70 | (0.58, 0.84) | 8 | 60.8%, (0.013) |  |
 CPS < 10 | 0.82 | (0.74, 0.91) | 8 | 9.7%, (0.355) |  | 0.75 | (0.57, 0.97) | 5 | 72.1%, (0.006) |  |
TPS = 1% |  |  |  |  | 0.000 |  |  |  |  | 0.341 |
 TPS ≥ 1% | 0.66 | (0.60, 0.73) | 13 | 17.2%, (0.270) |  | 0.73 | (0.59, 0.91) | 9 | 63.6%, (0.005) |  |
 TPS < 1% | 0.86 | (0.80, 0.92) | 12 | 32.2%, (0.133) |  | 0.87 | (0.66, 1.13) | 8 | 86.9%, (0.000) |  |
TPS = 5% |  |  |  |  | 0.037 |  |  |  |  | 0.068 |
 TPS ≥ 5% | 0.64 | (0.55, 0.73) | 6 | 0.0%, (0.902) |  | 0.52 | (0.43, 0.63) | 3 | 0.0%, (0.844) |  |
 TPS < 5% | 0.77 | (0.69, 0.85) | 6 | 0.0%, (0.590) |  | 0.65 | (0.56, 0.75) | 3 | 43.6%, (0.170) |  |
TPS = 10% |  |  |  |  | 0.036 |  |  |  |  | 0.121 |
 TPS ≥ 10% | 0.63 | (0.54, 0.73) | 7 | 0.0%, (0.772) |  | 0.54 | (0.43, 0.66) | 4 | 0.0%, (0.657) |  |
 TPS < 10% | 0.76 | (0.69, 0.84) | 7 | 0.0%, (0.922) |  | 0.69 | (0.54, 0.88) | 4 | 68.6%, (0.023) |  |